Sector revisions Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.89 USD | +3.32% |
|
-28.27% | +0.83% |
| 07-31 | Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial | MT |
| 07-31 | Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 6 | |||||||
| 23 | |||||||
| 21 | |||||||
| 18 | |||||||
| 27 | |||||||
| 24 | |||||||
| 12 | |||||||
| - | 18 | ||||||
| 14 | |||||||
| 16 | |||||||
| 11 | |||||||
| 14 | |||||||
| 6 | |||||||
| 12 | |||||||
| 11 | |||||||
| 13 | |||||||
| 21 | |||||||
| 19 | |||||||
| 14 | |||||||
| 22 | |||||||
| Average | 16 | |||||||
| Weighted average by Cap. | 19 |
- Stock Market
- Stocks
- GLUE Stock
- Sector Monte Rosa Therapeutics, Inc.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
